Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma-Reference-Cited by-同舟云学术

Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-α2b in metastatic melanoma

Published:2006-04 Issue:4 Volume:17 Page:571-577
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Bajetta E.,Del Vecchio M.,Nova P.,Fusi A.,Daponte A.,Sertoli M.R.,Queirolo P.,Taveggia P.,Bernengo M.G.,Legha S.S.,Formisano B.,Cascinelli N.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/17/4/571/686402/mdl007.pdf

Reference30 articles.

1. Cancer Statistics, 2004;Jemal;CA Cancer J Clin,2004

2. Cancer: Principles and Practice of Oncology;Lotze,2001

3. Metastatic melanoma: chemotherapy;Bajetta;Semin Oncol,2002

4. Management of cutaneous melanoma;Tsao;N Engl J Med,2004

5. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine and DTIC (CVD) for metastatic melanoma;Legha;Cancer,1989

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial;Cancer Treatment and Research Communications;2024-09

2. Tumor Lysate Particle Only Vaccine (TLPO) vs. Tumor Lysate Particle-Loaded, Dendritic Cell Vaccine (TLPLDC) to Prevent Recurrence in Resected Stage III/IV Melanoma Patients: Results of a Phase I/IIa Trial;2024-03-19

3. Characteristics of long-survivor metastatic melanoma after polychemotherapy and interferon: a retrospective study;Swiss Medical Weekly;2023-12-15

4. Slizničné melanómy a chirurgická liečba;Zubný lekár;2023-06-11

5. Targeting ferroptosis as a cell death pathway in Melanoma: From molecular mechanisms to skin cancer treatment;International Immunopharmacology;2023-06